Assessing the value of biopharmaceutical innovation in key therapy areas in middle-income countries

Statement 20 Mar 2023

WHO Intergovernmental Negotiating Body (INB) intersessional briefing on the “Transfer of technology and know-how”

On 20 March, IFPMA delivered a shortened version of the below statement at the WHO INB intersessional briefing on “Article 7: Access to technology: promoting sustainable and equitably distributed production and transfer of technology and know-how” of the WHO convention, agreement, or other international instrument on pandemic prevention, preparedness, and response (“WHO CA+”).

Statement to the IHR Review Committee on amendments to the International Health Regulations

IFPMA encourages the consistent coordination of the INB and IHR processes to ensure a non-duplicative, fit-for-purpose outcome for all.

Impact of a waiver of intellectual property rights for COVID-19 therapeutics

As WTO Member States continue to discuss an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics, latest evidence and data published today explains what the consequences of such a waiver would have on industry’s ability to fight the COVID-19 pandemic.